Company Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $1.20M (-49.9% YoY); net profit $-22.70M.
- Trailing 12 Months Year-on-year growth — revenue -9.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -26.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -26.60% |
| 1 Year: | -9.20% |
Stock Price Performance
| 1 Year: | +673.26% |
| 6 Months: | +25.47% |
| 3 Months: | -11.80% |
| 1 Month: | -13.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -26.6% CAGR over 5 years.
- Trading 42.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LGVN Longeveron Inc. PHARMA | 6.65 | -0.67 | $20.24M | 0.00% | - | - | -26.60% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 217.00K | 150.00K | 548.00K | 468.00K | 773.00K | 381.00K | 316.00K | 137.00K | 398.00K |
| Gross Profit | 812.00K | 112.00K | 373.00K | 149.00K | 208.00K | 164.00K | 165.00K | 160.00K | 92.00K | 76.00K | 93.00K | 54.00K | 329.00K | 344.00K | 682.00K | 275.00K | 146.00K | 125.00K | 264.00K |
| Operating Income | -213.00K | -1.23M | -958.00K | -3.46M | -5.06M | -4.91M | -3.39M | -4.22M | -5.19M | -4.72M | -5.71M | -5.16M | -4.09M | -3.50M | -4.65M | -5.18M | -5.40M | -7.31M | -4.78M |
| Net Income | -213.00K | -1.22M | - | -3.11M | -5.01M | -4.86M | -3.51M | -5.62M | -5.24M | -4.65M | -5.63M | -5.11M | -4.06M | -3.41M | -4.42M | -5.01M | -5.03M | -7.22M | -4.74M |
| Diluted EPS | - | - | - | - | -0.26 | -0.25 | -0.17 | -0.27 | -0.25 | -2.21 | -2.67 | -2.79 | -1.61 | -1.83 | -0.34 | -0.34 | -0.33 | -0.39 | -0.19 |
| R&D Expense | 289.00K | 642.00K | 585.00K | 1.35M | 1.96M | 2.05M | 1.29M | 1.72M | 2.96M | 2.78M | 2.29M | 1.84M | 2.22M | 1.72M | 2.21M | 2.52M | 2.95M | 3.85M | 2.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5.63M | 1.31M | 1.22M | 709.00K | 2.39M | 1.20M |
| Gross Profit | 1.83M | 590.00K | 497.00K | 221.00K | 1.88M | 803.00K |
| Operating Income | -3.78M | -17.46M | -18.04M | -21.03M | -16.52M | -23.29M |
| Net Income | -3.72M | -17.05M | -18.84M | -21.41M | -15.97M | -22.70M |
| Diluted EPS | - | -0.90 | -0.90 | -10.22 | -2.62 | -1.29 |
| R&D Expense | 2.67M | 7.09M | 9.37M | 9.07M | 8.14M | 12.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.24M | 42.77M | 27.41M | 12.08M | 25.56M | 10.26M |
| Total Equity | 4.45K | 1.96M | 37.45M | 20.50M | 6.74M | 21.89M | 5.67M |
| Cash & Equivalents | - | 816.00K | 25.66M | 10.50M | 4.95M | 19.23M | 4.66M |
| Long Term Debt | - | 311.00K | - | - | - | - | - |
| Total Liabilities | - | 7.28M | 5.31M | 6.91M | 5.34M | 3.67M | 4.59M |
| Current Liabilities | - | 3.83M | 2.71M | 4.87M | 3.89M | 2.58M | 4.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.36M | -9.64M | -13.97M | -19.00M | -13.87M | -18.64M |
| Investing Cash Flow | -261.00K | -10.70M | -677.00K | 8.19M | -640.00K | -595.00K |
| Financing Cash Flow | 1.57M | 45.17M | -509.00K | 5.26M | 28.79M | 4.67M |
| Capital Expenditure | -131.00K | -330.00K | -569.00K | -301.00K | -655.00K | -245.00K |
| Free Cash Flow | -2.50M | -9.97M | -14.54M | -19.30M | -14.52M | -18.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 32.4% | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% |
| Operating Margin % | -67.1% | -1,336.6% | -1,476.5% | -2,966.0% | -690.7% | -1,942.2% |
| Net Margin % | -66.1% | -1,305.1% | -1,541.3% | -3,020.2% | -667.8% | -1,893.6% |
| ROE % | -190.1% | -45.5% | -91.9% | -317.7% | -73.0% | -400.1% |
| ROCE % | -69.8% | -43.6% | -80.0% | -256.8% | -71.9% | -377.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Millennium Management Llc | 4.45% | 135.39K | $337.12K |
| 2 | Logos Global Management LP | 4.23% | 128.70K | $320.46K |
| 3 | Vanguard Capital Management LLC | 1.91% | 58.13K | $144.75K |
| 4 | Blackrock Inc. | 0.74% | 22.42K | $55.82K |
| 5 | Geode Capital Management, LLC | 0.67% | 20.38K | $50.74K |
| 6 | Jane Street Group, LLC | 0.63% | 19.04K | $47.40K |
| 7 | Vanguard Fiduciary Trust Co | 0.46% | 14.01K | $34.89K |
| 8 | Mariner, LLC | 0.41% | 12.60K | $31.37K |
| 9 | Adar1 Capital Management, LLC | 0.36% | 10.84K | $26.99K |
| 10 | Beacon Pointe Advisors, LLC | 0.33% | 10.00K | $24.90K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LGVN
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE4wWWl1M3FyZEFOM0E5OGVkYmc0VDRQRHpHcUNZUHVMSXhyT0p6eVFudzRaX2VpLUUyblpQR2J4X05wYVltaVY0cg?oc=5" target="_blank">Longeveron Stock Price Forecast. Should You Buy LGVN?</a> …
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPSmRpczNvQUpFTDNra1JscmotM2FfcV96bHBKcmtCa2lxZ2lIdE5tcGdoRzhZMGJsSkM3djhEVGVjV0ljTnlMQWtnQjNZWDhyckZmSHhUQWNEUm5BbkNGNGcwN1Z2ZGFvVTY0a0xzVy1WZG9vd0NHQ21LVFlGYWwwZ3NydVJ0WXpiVVM5Y3…
Trading Systems Reacting to (LGVN) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZkZDa2Y4YVRTWGZJUFdkQnRGYXVzdHdKSG4yajBPNXF4UkNmN3gySGhvVW92b0d5Rkd2VzFJbmdQbjgzS0JpcmNXOWRMamhvYXhLUFA0RnZqb01NTkhSNEdNMi1fcnNPVUozWGRhSWpzcGxNWlpXLXFYN3BSMDNCUElKS3dKREJOMGdqYW…
A biotech presentation is set for New York on Sept. 14 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSm5jUVplQXgyNW5wR1F4a2x3YzM3b2tvRDkyMDVxbmREMjB3TXNaMmh0Sl9KeTQ4eml5WWZuT2ZNTk9uWWt3dXd0U2pfM2VubU1wcjdvNTJJNVdkcVloMS1wMkZPRHFuQ095TDRxVGo0M3BHcXpGTzJ1cG9USUJfTFc1WVViTmgwNmpZWV…
A $30 Million Reason to Buy Penny Stock Longeveron Today - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1nUm9ucDdJVnV2NmcxSlNqSnlDeEZvZGtaTWdkbGlTSTlVUkVkcm9JOG8tMkhqZUtEUFBkbGNHUTA1M3l4bzBCdGFVZmU0UjN3eTllUXJvSUY0VE9CaEZpSWg5dzFTakhPTVUtYXFYU1JBOTRuWDd0Q2hRbXRPQQ?oc=5" target="_blan…
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQMnZNMnJxRm1GQ0w1Zks1WHpSMFlNQjcyalhQeEVURUE4cWpCa0otdDBpeGNPUkpaZkpFb2NXMDlMaFhhMzYxWFc0eG5rMDVSVUxxQ2kzcXdqVlB3bjc3N085RXJFd05sWTAyNkkwM0NyYVBLdVYtWVVESzZTc0lxMWRqTzV5RlpIV083ND…
LGVN — Frequently Asked Questions
What is the current share price of Longeveron Inc. (LGVN)?
As of 2026-09-19 21:16 PDT, Longeveron Inc. (LGVN) trades at $6.65 on NasdaqCM. Its 52-week range is $0.75 to $11.60.
What is the market capitalisation of LGVN?
Longeveron Inc. (LGVN) has a market capitalisation of $20.24M on NasdaqCM.
What is the P/E ratio of LGVN?
LGVN trades at a trailing price-to-earnings (P/E) ratio of -0.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.76.
Is LGVN a good stock to buy?
This page provides a data-driven analysis of Longeveron Inc. (LGVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.